



Republic of the Philippines
Department of Health

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-305

25 May 2018

RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT FOR ITEM NO. 1 FOR THE PROCUREMENT OF CYTARABINE IB NO. 2018-167

WHEREAS, Open Competitive Bidding for the Procurement of Cytarabine was conducted in accordance with Republic Act (RA) 9184 and its 2016 Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2018 with a Total Approved Budget for the Contract (ABC) of **One Million Seven Hundred Three Thousand Two Hundred Fourteen Philippine Pesos (PhP1,703,214.00)**;

| Item No. | Description | Qty. | Unit | Total ABC (PhP) |
|----------|------------------|-------|------|-----------------|
| 1 | Cytarabine 1gram | 400 | Vial | 533,172.00 |
| 2 | Cytarabine 500mg | 900 | Vial | 351,342.00 |
| 3 | Cytarabine 100mg | 6,000 | Vial | 818,700.00 |
| TOTAL | | | | 1,703,214.00 |

WHEREAS, on 02 February 2018, the Central Office Bids and Awards Committee (COBAC)-A received Purchase Requests (PRs) from Disease Prevention and Control Bureau- Lifestyle Related Diseases Division (DPCB-LRDD);

WHEREAS, on 09 February 2018, a Pre-procurement Conference took place as scheduled at 9:00 A.M at the COBAC Conference Room, Department of Health (DOH), to determine the readiness of the procurement at hand;

WHEREAS, on 12 February 2018, the COBAC-A issued a memorandum to the End-user, DPCB-LRDD, requesting confirmation on the comments/suggestion made during the Pre-procurement Conference;

WHEREAS, on 13 February 2018, a response from DPCB-LRDD was received and informing that the revised PRs were already forwarded to Pharmaceutical Division (PD) for clearance;

WHEREAS, on 20 February 2018, a revised PRs were received and reflecting the changes on the ABC;

WHEREAS, on 22 and 28 of February 2018, the COBAC-A issued memoranda to DPCB-LRDD following-up the submission of Allocation List;

WHEREAS, on 28 February 2018, Allocation List was received;

WHEREAS, on 05 March 2018, the Invitation to Bid was published and posted in the PhilGEPS Website and other conspicuous places within the premises of the DOH. The advertisement of the IB in a newspaper of general nationwide circulation provided in Section 21.2.1 (c) of the 2016 IRR of RA 9184 shall not be required for contracts to be bid with an approved budget of PhP10M and below for the procurement of goods;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-113 dated 06 March 2018;

WHEREAS, on 13 March 2018, a Pre-bidding Conference took place as scheduled at 10:00 A.M. at the COBAC Conference Room, DOH, with one (1) prospective bidder attending, namely, Metro Drug, Inc. (MDI);

WHEREAS, on 14 March 2018, the COBAC-A issued a memorandum to DPCB-LRDD, requesting confirmation on the comments/suggestion made during the Pre-bidding Conference;

WHEREAS, on 20 March 2018, the COBAC-A issued a memorandum following-up the submission of the revised PRs;

WHEREAS, a Bid Bulletin No. 1, dated 21 March 2018 was issued to announce the postponement for the Submission and Opening of Bids previously stated on 27 March 2018;

WHEREAS, a Bid Bulletin No. 2, dated 26 March 2018 was issued clarifying the issues and concerns raised during the Pre-bidding Conference and to announce the new schedule of the Submission and Opening of Bids;

WHEREAS, on 03 April 2018, the Submission of Bids took place as re-scheduled at 9:00 A.M. at the COBAC Conference Room, DOH;

WHEREAS, two (2) prospective bidders purchased the bidding documents and submitted their respective proposals, namely:

1. Zuellig Pharma Corporation (ZPC); and,
2. Globo Asiatico Enterprises, Inc. (GAEI).

WHEREAS, Notice of Change of Schedule dated 03 April 2018 was issued to announce the new schedule of the Opening of Bids from 03 April 2018 to 06 April 2018;

WHEREAS, the Opening of Bids took place as re-scheduled on 06 April 2018 at 9:00 A.M. at the COBAC Conference Room, DOH;

WHEREAS, the first envelopes, containing the Eligibility and Technical Documents were individually opened and the presence, completeness and correctness of all the documents were individually verified by the COBAC-A in the presence of the prospective bidders' representatives. Upon checking, ZPC JV with Interphil Laboratories, Inc. (ICI) and GAEI were declared "ELIGIBLE";

WHEREAS, the second envelopes containing the Financial Proposals were opened and the presence, completeness and correctness of the documents were verified by the COBAC-A. Upon examination, the two (2) "ELIGIBLE" bidders were rated "PASSED", and subsequently their respective proposals were read out publicly and posted in the Abstract of Bids, to wit:

| | | | | 1 | 2 | |
|-----------------|------------------|-------|------|-------------------|-------------------------|------------|
| Name of Company | | | | ZPC JV WITH ILI | GAEI | |
| Bid Security | | | | BSD | BSD | |
| Amount | | | | N/A | N/A | |
| Validity | | | | N/A | N/A | |
| REMARKS | | | | ELIGIBLE & PASSED | | |
| Item No. | Item Description | Qty. | Unit | TOTAL ABC (Php) | BID PRICE AS READ (Php) | |
| 1 | Cytarabine 1gram | 400 | Vial | 533,172.00 | 346,800.00 | 235,200.00 |
| 2 | Cytarabine 500mg | 900 | Vial | 351,342.00 | 313,200.00 | NO BID |
| 3 | Cytarabine 100mg | 6,000 | Vial | 818,700.00 | 688,500.00 | NO BID |
| TOTAL | | | | 1,703,214.00 | 1,348,500.00 | 235,200.00 |

WHEREAS, GAEI was declared as the Lowest Bidder for Item No. 1 and ZPC JV with ILI was declared as the Single Bidder for Item No. 2 and Item No. 3 subject to further arithmetical review and corrections of the financial bid, to determine the bonafide Lowest Calculated Bidder;

WHEREAS, the bids for the items listed below were found to be substantially complying:

| Item No. 1: 400 vials of Cytarabine 1gram | | | | |
|---|-----------------|------------|--------------------------------|---------------------|
| Bidder No. | Name of Company | ABC (Php) | Bid as Calculated Amount (Php) | % Variance from ABC |
| 2 | GAEI | 533,172.00 | 235,200.00 | 55.89% |
| 1 | ZPC JV with ILI | | 346,800.00 | 34.96% |

| Item No. 2: 900 vials of Cytarabine 500mg | | | | |
|---|-----------------|------------|--------------------------------|---------------------|
| Bidder No. | Name of Company | ABC (Php) | Bid as Calculated Amount (Php) | % Variance from ABC |
| 1 | ZPC JV with ILI | 351,342.00 | 313,200.00 | 10.86% |

Item No. 3: 6,000 vials of Cytarabine 100mg

| Bidder No. | Name of Company | ABC (Php) | Bid as Calculated Amount (Php) | % Variance from ABC |
|------------|-----------------|------------|--------------------------------|---------------------|
| 1 | ZPC JV with ILI | 818,700.00 | 688,500.00 | 15.90% |

WHEREAS, on 10 April 2018, the detailed initial evaluation of the submitted proposals on the legal, technical and financial aspects of the documents of the LCB was undertaken by the designated TWG;

WHEREAS, on 17 April 2018, the TWG submitted their initial report and requested GAEI for clarification on the Technical and Legal requirements;

WHEREAS, on 24 April 2018, the cited TWG Report was presented to the COBAC-A during its 17th Regular Meeting;

WHEREAS, on 25 April 2018, the COBAC-A issued a letter to GAEI requesting for clarification on the above-cited findings;

WHEREAS, on 27 April 2018, the COBAC-A received a response from GAEI and it was subsequently forwarded to the designated TWG for further evaluation;

WHEREAS, on 07 May 2018, the TWG submitted their consolidated report and found GAEI “Complying” with the Technical and Legal requirements;

WHEREAS, on 09 May 2018, the cited TWG report was presented to COBAC-A during its 18th Regular Meeting. Upon deliberation, the COBAC-A concurred with the TWG and decided to proceed with the post-qualification evaluation upon receipt of post-qualification documents;

WHEREAS, on the same date, a notification was issued to GAEI, requesting for the submission of post-qualification requirements;

WHEREAS, on 11 May 2018, GAEI submitted its post-qualification requirements and subsequently was forwarded to the TWG, for evaluation;

WHEREAS, on 18 May 2018, the TWG found GAEI “responsive” on its post-qualification documents and submitted their post-qualification report;

WHEREAS, on 22 May 2018, the TWG Reports was presented to COBAC-A during its 20th Regular Meeting concurred with the TWG report and recommended the award of contract in favor of GAEI for Item No. 1;

WHEREAS, on 25 May 2018, the TWG submitted the Bid Evaluation and Post Qualification Evaluation Reports citing GAEI “responsive” on the submitted documents;

WHEREAS, the COBAC-A reviewed and deliberated the TWG reports, as well as the documents submitted by GAEI. The following are the salient points of discussion:

| Item No. | Description | Name of Bidder | Bidder's Rank | ABC (Php) | Bid Price (Php) | TWG | | COBAC | |
|----------|---------------------|----------------|---------------|------------|-----------------|--|----------------|---|---|
| | | | | | | Finding | Recommendation | Finding | Recommendation |
| 1 | Cytarabine 1gram | GAEI | LCB | 533,172.00 | 235,200.00 | The LCB passed the post qualification and found to have complied with the legal, technical and financial requirements. | Responsive | • COBAC confirms the recommendation of the TWG. • GAEI is determined to be responsive and post-qualified and recommended for the award of contract for Item No. 1. | Lowest Calculated Responsive Bid (LCRB) |

WHEREAS, at the time of the signing of this resolution, there is no pending incident, no pending Motion for Reconsideration, no pending Protest and the COBAC-A followed the requirements set forth in R.A. 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A **HEREBY RESOLVE** to recommend the following:

1. Recommend the award of contract to **Globo Asiatico Enterprises, Inc.** determined as the LCRB with a Total Contract Price of **Two Hundred Thirty Five Thousand Two Hundred Philippine Pesos (Php235,200.00)** inclusive of other taxes for the item listed below:

| Item No. | Particular | Qty. | Unit | Total Amount (Php) |
|----------|-------------------|------|------|--------------------|
| 1 | Cytarabine 1 gram | 400 | Vial | 235,200.00 |

2. Issue another resolution for the items listed below upon receipt of the TWG Evaluation Report:

| Item No. | Description | Qty. | Unit | Total ABC (Php) |
|----------|------------------|-------|------|-----------------|
| 2 | Cytarabine 500mg | 900 | Vial | 351,342.00 |
| 3 | Cytarabine 100mg | 6,000 | Vial | 818,700.00 |

JUN 22 2018

Signed this ___ day of ___ 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) – A

[Signature]
LEONTA P. GORCOLON, MHA, MCHM, CEO VI
Regular Member

[Signature]
FERCHOL AVELINO, MD, PHSAE
Regular Member

[Signature]
KENNETH G. RONQUILLO, MD, MPH, CESO III
Vice-Chairperson

[Signature]
MAR WYNN C. BELLO, MD, MPA
Regular Member

NESTOR F. SANTIAGO, JR., MD, MPH, CHS, CESO III
Assistant Secretary of Health
Chairperson

By Authority of the Secretary of Health:

[Signature]
MYRNA C. CABOTAJE, MD, MPH, CESO III
Director IV
JUL 09 2018
Disease Prevention and Control Bureau